Tobemstomig is another PD-1/LAG-3 bsAb that is currently in a phase 1b/2 study under the MORPHEUS-LIVER program, evaluating novel combinations with atezolizumab and bevacizumab in first-line HCC [77] (Table 2). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.